Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 03

858P - Automated detection of melanoma: Comparing a convolutional neural network (CNN) approach with an algorithm assessing disorder in the pattern of pigmented lesions, intended to mimick onco-dermatologists' visual analysis

Date

10 Sep 2022

Session

Poster session 03

Topics

Tumour Site

Melanoma

Presenters

Jilliana Monnier

Citation

Annals of Oncology (2022) 33 (suppl_7): S356-S409. 10.1016/annonc/annonc1059

Authors

J. Monnier1, A.C. Gouabou Foahom2, M. Serdi2, J. Collenne2, R. Iguernaissi2, C. Gaudy Marqueste3, J. Damoiseaux2, J.J. Grob4, D. Merad2

Author affiliations

  • 1 Centre De Recherche En Cancerologie De Marseille, Laboratoire D'informatique Et Systèmes, Dermatology and skin cancers department, La Timone hospital, AP-HM, Aix-Marseille University, 13005 - Marseille/FR
  • 2 The Computer And Science Systems Laboratory, Aix-Marseille University -Faculté des Sciences de Luminy, 13288 - Marseille/FR
  • 3 Dermatology Departement And Skin Cancer, La Timone Hospital, Ap-hm, Centre De Recherche En Cancerologie De Marseille, Aix-Marseille University, 13385 - Marseille/FR
  • 4 Dermatology Departement And Skin Cancer, La Timone Hospital, Ap-hm Centre De Recherche En Cancerologie De Marseille, Aix-Marseille University, 13005 - Marseille/FR

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 858P

Background

Among Computer Aided Diagnosis (CAD) systems for melanoma detection, CNN behaves as a “black box”, using a huge number of unknown features from a lesion’s image to come to a classification and where no expert input can be implemented. Conversely of hand-crafted methods, the expert is selecting features to be used for the lesions' classification. Most of these hand-crafted algorithms were based on ABCD criteria (asymmetry, border, color, diameter). However the unconscious process leading onco-dermatologists to arbitrate between nevi and melanoma is more likely based on a global cognitive assessment, which we hypothezise to be an overall perception of order/disorder in the pattern of pigmented lesions. Our objective was to design an hand-crafted model based on the concept of ordered/disordered pattern, and to assess its performances by comparison to a CNN model, for the classification melanoma versus nevus.

Methods

We trained and tested 2 algorithms on a dermoscopic images dataset of 1533 melanomas and 6124 nevi. First, we developped The "Disorder model" based on a hand-crafted method, we extracted 4 specific features to characterize melanoma disorder named entropy, skewness, standard deviation and kurtosis, from 4 colors spaces. The classification of melanoma versus nevi was based on a statistical clustering method (KNN algorithm). Second, we developped a CNN model on the same dataset.

Results

Performances of the CNN model yielded: AUC 0.89, sensitivity 86%, specificity 75%, balanced accuracy 81%. The “Disorder model” reached similar high performances: AUC 0.91, sensitivity 91%, specificity 74%, balanced accuracy 82.5%. A statistical χ2 test revealed that entropy, characterizing color disorder, was the most discriminative feature for melanoma detection.

Conclusions

This study shows that an algorithm attempting to mimick human brain ability, using a few features to assess the disorder pattern in pigmented lesions, can reach a level of performance for melanoma detection equivalent to CNN-based algorithm, which is using much more features. Entropy seems to be a key feature to assess pattern disorder of pigmented lesions.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

J.J. Grob and D. Merad.

Funding

Aderem group.

Disclosure

J. Monnier: Financial Interests, Institutional, Invited Speaker: BMS. C. Gaudy Marqueste: Financial Interests, Institutional, Invited Speaker: BMS, Roche. J.J. Grob: Financial Interests, Institutional, Invited Speaker: BMS, Amgen, MSD, Novartis, Roche, Pierre Fabre, Merck, Pfizer. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.